AIM: To assess prospectively small bowel stenoses in Crohn's disease (CD) patients treated with infliximab using Small Intestine Contrast Ultrasonography (SICUS). METHODS: Twenty patients (M 12, age, 42.7 +/- 11.8 years), 15 of whom showed obstructive symptoms indicating the presence of small bowel stenosis, and 5 without stenosis, were treated with infliximab (5 mg/kg at wk 0, 2, 6 and 5 mg/kg every 8 wk thereafter) for steroid refractoriness, fistulizing disease, or to avoid high-risk surgery. SICUS was performed at the induction phase and at regular time intervals during the follow-up period of 34.7 +/- 16.1 mo (range 7-58). Small bowel stenoses were detected by SICUS, endoscopy and MRI. RESULTS: In no case was progression of stenoses or the appearance of new ones seen. Of the 15 patients with stenosis, 5 stopped treatment after the induction phase (2 for no response, 3 for drug intolerance, one of whom showed complete regression of one stenosis). Among the remaining 10 patients, a complete regression of 8 stenoses (1 stenosis in 5 patients and 3 stenoses in one patient) was observed after 6-22 infliximab infusions. CONCLUSION: In patients with CD treated with infliximab we observed: (a) No progression of small bowel stenosis and no appearance of new ones, (b) Complete regression of 1/22 stenosis after the induction phase and of 8/15 (53.3%) stenosis after 6-22 infusions during maintenance therapy.
AIM: To assess prospectively small bowel stenoses in Crohn's disease (CD) patients treated with infliximab using Small Intestine Contrast Ultrasonography (SICUS). METHODS: Twenty patients (M 12, age, 42.7 +/- 11.8 years), 15 of whom showed obstructive symptoms indicating the presence of small bowel stenosis, and 5 without stenosis, were treated with infliximab (5 mg/kg at wk 0, 2, 6 and 5 mg/kg every 8 wk thereafter) for steroid refractoriness, fistulizing disease, or to avoid high-risk surgery. SICUS was performed at the induction phase and at regular time intervals during the follow-up period of 34.7 +/- 16.1 mo (range 7-58). Small bowel stenoses were detected by SICUS, endoscopy and MRI. RESULTS: In no case was progression of stenoses or the appearance of new ones seen. Of the 15 patients with stenosis, 5 stopped treatment after the induction phase (2 for no response, 3 for drug intolerance, one of whom showed complete regression of one stenosis). Among the remaining 10 patients, a complete regression of 8 stenoses (1 stenosis in 5 patients and 3 stenoses in one patient) was observed after 6-22 infliximab infusions. CONCLUSION: In patients with CD treated with infliximab we observed: (a) No progression of small bowel stenosis and no appearance of new ones, (b) Complete regression of 1/22 stenosis after the induction phase and of 8/15 (53.3%) stenosis after 6-22 infusions during maintenance therapy.
Authors: E Louis; C Ribbens; A Godon; D Franchimont; D De Groote; N Hardy; J Boniver; J Belaiche; M Malaise Journal: Clin Exp Immunol Date: 2000-05 Impact factor: 4.330
Authors: G D'haens; S Van Deventer; R Van Hogezand; D Chalmers; C Kothe; F Baert; T Braakman; T Schaible; K Geboes; P Rutgeerts Journal: Gastroenterology Date: 1999-05 Impact factor: 22.682
Authors: M D Baugh; M J Perry; A P Hollander; D R Davies; S S Cross; A J Lobo; C J Taylor; G S Evans Journal: Gastroenterology Date: 1999-10 Impact factor: 22.682
Authors: Emma Calabrese; Francesco La Seta; Antonio Buccellato; Roberto Virdone; Nadia Pallotta; Enrico Corazziari; Mario Cottone Journal: Inflamm Bowel Dis Date: 2005-02 Impact factor: 5.325
Authors: Ian C Lawrance; Feng Wu; André Z A Leite; Joseph Willis; Gail A West; Claudio Fiocchi; Shukti Chakravarti Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: Cécile Campos; Antoine Perrey; Céline Lambert; Bruno Pereira; Marion Goutte; Anne Dubois; Felix Goutorbe; Michel Dapoigny; Gilles Bommelaer; Constance Hordonneau; Anthony Buisson Journal: Dig Dis Sci Date: 2017-04-11 Impact factor: 3.199
Authors: Amanda B Muir; Kara Dods; Yuli Noah; Sarit Toltzis; Prasanna Modayur Chandramouleeswaran; Anna Lee; Alain Benitez; Adam Bedenbaugh; Gary W Falk; Rebecca G Wells; Hiroshi Nakagawa; Mei-Lun Wang Journal: Exp Cell Res Date: 2014-08-27 Impact factor: 3.905
Authors: Sara El Ouali; Benjamin Click; Stefan D Holubar; Florian Rieder Journal: United European Gastroenterol J Date: 2020-01-14 Impact factor: 4.623
Authors: Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder Journal: Expert Rev Gastroenterol Hepatol Date: 2020-12-28 Impact factor: 3.869